| Literature DB >> 31448277 |
Amanda Leitolis1, Anny W Robert1, Isabela T Pereira1, Alejandro Correa1, Marco A Stimamiglio1.
Abstract
Pluripotent stem cells (PSC) can be used as a model to study cardiomyogenic differentiation. In vitro modeling can reproduce cardiac development through modulation of some key signaling pathways. Therefore, many studies make use of this strategy to better understand cardiomyogenesis complexity and to determine possible ways to modulate cell fate. However, challenges remain regarding efficiency of differentiation protocols, cardiomyocyte (CM) maturation and therapeutic applications. Considering that the extracellular milieu is crucial for cellular behavior control, cardiac niche studies, such as those identifying secreted molecules from adult or neonatal tissues, allow the identification of extracellular factors that may contribute to CM differentiation and maturation. This review will focus on cardiomyogenesis modeling using PSC and the elements involved in cardiac microenvironmental signaling (the secretome - extracellular vesicles, extracellular matrix and soluble factors) that may contribute to CM specification and maturation.Entities:
Keywords: cardiomyocytes; cell differentiation; maturation; pluripotent stem cell; secretome
Year: 2019 PMID: 31448277 PMCID: PMC6695570 DOI: 10.3389/fcell.2019.00164
Source DB: PubMed Journal: Front Cell Dev Biol ISSN: 2296-634X
FIGURE 1Schematic representation of the initial steps of cardiac lineage commitment. Indication of signaling pathways that influence each differentiation stage and the specific cellular markers expressed during lineage differentiation. FHF, first heart field. SHF, second heart field.
Three major in vitro cardiac differentiation protocols.
| direct coculture or END-2 conditioned medium | ||
| spontaneous differentiation | ||
| growth factors in defined media (GFs) | ||
| growth factors in defined media (GFs) | ||
| small molecules in defined media (SM) | ||
Summary of transcriptomic and proteomic studies based on hPSC cardiac differentiation.
| Monolayer in END-2 coculture | Days 0, 1, 3, 6, 9, and 12 | Agilent Microarray | Identification and validation of time-dependent gene expression patterns | |
| EB spontaneous differentiation | hESC, CM, and hF heart | Agilent Microarray | hESC-CM promoting recovery from cardiac ischemia reperfusion injury | |
| EB in END-2 conditioned medium | hESC, EBs, CM-Day 21, fetal heart and adult heart | Illumina microarray | Evaluation of the biological relevance of uncharacterized genes | |
| EB (GFs) | Days 0, 2, 5, 9, and 14 | ChIP-seq and Affymetrix array | Temporal alterations in chromatin structure identify key regulators of cardiovascular development | |
| EB (GFs) KDRlow/CD166 + | hESC or iPS, M-Day 6, Day 20: CM, SMC, EC | Illumina RNA-seq | Lineage-enriched genes and lncRNAs, RNA splicing isoforms | |
| Monolayer (SM/C) | hESC, D3, D4 and CM-D31 | Illumina RNA-seq and MDB-seq | TFs, miRNAs, lncRNAs and methylome | |
| Monolayer (GFs, SM/C) * Day 3 MESP1 + sorting | Days 0, 3, 5, 7, 10, and 14 | Illumina Microarray | Regulation of ECM components and new cell surface markers | |
| Monolayer cardiomyocyte differentiation kit (Thermo Fisher Scientific) | Days 0, 2, 4, and 30 | RNA-seq and ATAC-seq | Mapping open chromatin patterns | |
| Monolayer (GFs) | Days 0, 12 and 20 | Illumina Microarray and ChIP-seq | Genetic and epigenetic changes and a role for NR2F2 | |
| Monolayer (SM/C) | Days 0, 2, 5, 15, and 30 | Illumina single-cell RNA-seq | Cardiomyocyte hypertrophy and maturation | |
| Monolayer (SM/C) | Days 0, 5, 14, and 45 | Single-cell RNA-seq | Single-cell heterogeneity | |
| EB (SM/C) | Days 0, 2, 5, 15 and 30 | Illumina RNA-seq and RRB-seq | TFs, lincRNAs and DNA methylation changes | |
| EB (GFs) | Days 0, 1, 4, 9, and 15 | Illumina RNA-seq polysome | Polysomal RNAs and post-transcriptional regulation | |
| Monolayer (SM/C) | Days 0, 2, 5, and 14 | RNA-seq and ATAC-seq | Interplay of local and global chromatin structure on gene regulation | |
| Monolayer in END-2 coculture | differentiated hESC, enriched populations of hESC-derived CM and primary hF CM | SILAC-based quantitative MS | Identification of cell surface proteins for antibody-based selection | |
| EB (GFs) | hESC, hESC-VCMs, hF-VCMs, and hA-VCMs. | 2D-Differential-In-Gel Electrophoresis followed by MS | Metabolic and mitochondrial maturation | |
| Monolayer (GFs, SM/C) | Days 0, 5, and 14 | label-free quantitative | Identification of known and unknown regulatory proteins | |
| Monolayer (SM/C) | Days 0, 20, and 35 | SILAC-labeled | Metabolic and cytoskeletal proteins | |
| Monolayer (SM/C) | Days 0, 7, and 15 | SILAC upon PAL-based capture of sialylated glycoproteins (glyco-proteomic) | Global proteomic, sialo-glycoproteomic, and glycomic characterization | |
| Monolayer (SM/C) | Days 0, 5, and 15 | Three-plex tandem mass tag labeling | Identification of proteins associated with branched chain amino acid degradation and ketogenesis |
FIGURE 2Types of interactions at the cell–niche interface. In (1), a representative interaction between the cell and ECM is shown, whereas the matrikine-receptor interaction is pictured alongside the scissor, which represents matrix proteases. The ECM can also bind to and present a given trophic factor to the cell, as depicted in (2). The typical cytokine–receptor interaction is shown in (3). Cell-to-cell interactions are illustrated in (4), both by interacting membrane adhesive proteins and through ECM-integrin-mediated interaction. Finally, extracellular vesicle-driven signaling is represented in (5).
FIGURE 3Scheme of different approaches to isolate the cardiac secretome. Extracellular matrix, soluble factors and extracellular vesicles can be obtained from the cardiomyogenic developmental process (using hPSC) or from adult tissues through the use of different strategies. The process of hPSC cardiac differentiation can occur using 2D (monolayer) or 3D (embryoid bodies) cultures. On the other hand, with fragments of neonate or adult heart, we could isolate specific cell populations from the tissue (e.g., fibroblasts, cardiac progenitors) or culture the entire or parts of the cardiac tissue.
Summary of ECM approaches to improve PSC cardiomyogenic differentiation and/or PSC-CM maturation.
| Whole organ | Mouse ECM. Injected cells. | hESC or hESC-derived mesendodermal cells | After 14 days, both cell types expressed cardiac markers genes (cTnT, NKX2.5). No spontaneous contraction. | |
| Mouse ECM. Cells perfunded with growth factors. | hPSC-derived cardiac multipotent progenitors | Cells differentiate | ||
| Human ECM. Injected cells. Human heart bioreactor. | hiPSC-CM | After 14 days, cells remained viable, integrate with matrix and showed a range of maturity. No complete recellularization. | ||
| Slices | Mouse ECM. 60-μm thick slices. | mESC | Higher levels of cardiac markers in comparison with liver decellularized ECM. | |
| Porcine ECM. 150-μm thick slices. Laser-cut sheets. | hPSC-CM | Developed of an EHT for biomechanical characterization of PSC-CM. Cells presented organized sarcomeres and formed gap junctions. | ||
| Rat ECM. | MSCs and hPSC-derived ventricular CM | EHT with 75% CM and 25% MSC. After 2 weeks, cells formed a tissue-like structure with spontaneous contraction and CM, SMC and EC. | ||
| Human ECM from patients with end-stage non-ischemic dilated cardiopathy. 300-μm thick slices. | mESC, miPSC | Supported PSC proliferation. Increase expression of cardiac markers. | ||
| Human ECM. 400-μm thick slices. | PSC-CM | Spontaneous beating after 7–10 days. Better electrophysiological response. Uniform contraction, functional gap junctions. Increase expression of cardiac ion channels in CM. | ||
| Human ECM. 200-μm thick slices. Cardiac fiber bundles with 15 mm length, 2.5 mm diameter. Injected cells. | PSC-CM | Cells adhered, remained viable and functional. Spontaneous beating after 4–10 days. Maintenance in culture for 60–120 days. Formation of mechanical and electrical tissue. | ||
| Hydrogel | Different hydrogels composition: 75%, 25% or 0% of porcine ECM. | hESC EBs | The hydrogel composed of 75% porcine ECM:25% collagen increase the number of cells cTnT + Improve expression of Cx43, number of contracting cells and contraction amplitude. | |
| 2D (coating) or adult (cardiac patch) bovine adult and fetal ECM | hiPSC-CM | 3D cultures with adult tissue showed higher expression of mature cardiac genes. Increase calcium signaling. | ||
| 3D bioprinting | Porcine ECM. Different bioinks composition. | hCPC and/or MSC | Improve maturation of CPC. MSC + VEGF promoted vascular formation. | |
| Decellularized porcine ECM bioink. Custom digital light processing (DLP)-based scanningless and continuous 3D bioprinter. | hiPSC-CM | Improve expression of mature cardiac genes. | ||
| ECM proteins | Different proportions of fibronectin and laminin. | hESC | Ratio Fibronectin and Laminin (70:30) improve the number of differentiated cells (higher than 60% cTnI +). | |
| Systematic optimization of different ratios of type I collagen, laminin and fibronectin. | miPSC | Hydrogel composed of 61% type I collagen, 24% laminin-111 and 15% fibronectin increase number of cells (cTnT+). | ||
| Different combinations of laminin, fibronectin, types I, III and IV collagens. | hESC- derived CPC | Combinations of ECM proteins improve CPC attachment and survival. Fibronectin, types I, III and IV collagens showed better results. | ||
| Development of a Laminin-221 based cardiac differentiation protocol. | hESC | Combination of LN-521 + 221 matrix generated more CM (∼80%). High reproducibility confirmed by bulk and single-cell RNA-seq. | ||
| Biowire platform: Cells culture in type I collagen gel around a suture in a PDMS channel. Associate with electrical stimulation. | hPSC-CM and non-CM cells (e.g., FB, SMC, EC). | CM increase size, rod-like shape, organized sarcomeric banding, lower proliferative rate, improved Ca(+2) handling. | ||
| Matrigel | Cells encapsulated in 3D cardiac strips composed of matrigel and type I collagen. Associated with mechanical cyclic stretch. | hESC-CM associated or not with non-CM cells | Conditions with non-CM cells improve more CM maturation. Cyclic stretch improved sarcomere size and expression of mature cardiac genes. | |
| Cardiopatch hydrogel composed of matrigel, fibrinogen and cardiac media. | hPSC-CM | Improve expression of mature cardiac genes, sarcomeric banding, lower proliferative rate, more mature electrophysiology. | ||
| Coating with fibronectin or matrigel in glass coverslips or PDMS membranes. | hPSC-CM | Matrigel in PDMS improve CM electrophysiology, number of binucleated cells, expression of sarcomere and myofilament markers. | ||
| Matrigel Matress: 0.4–0.8 mm-thick of undiluted matrigel. | hiPSC-CM | CM developed rod-shape morphology, increase sarcomere size, upstroke velocity and expression of cardiac markers. | ||
| Cells culture in matrigel or hyaluronan-based hydrogel associated or not with pro-survival factors. | hiPSC-CM | |||
| Fibrin | 3D fibrin cardiac patch. | hESC-CM (SIRPA cells) | Improve sarcomere size, conduction velocity and expression of cardiac genes. | |
| 3D fibrin matrix. | hiPSC-CM | Increase sodium current density and upstroke velocity. | ||
| Fibrin hydrogels associated with stretch and electrical stimulation | hiPSC-CM | Early-stage iPSC-CM associated with physical conditioning at an increasing intensity accelerated maturation, showed superior electrophysiological properties, CMs with increase cell size and sarcomere length. |